Back To Search Results


Editor: Manouchkathe Cassagnol Updated: 10/10/2022 8:04:44 PM


Amiloride is a potassium-sparing diuretic that does not have much of a diuretic effect compared to its potassium-sparing activity.[1] It is a pyrazinoylguanidine derivative.[2] It is FDA indicated to be used adjunctively with thiazides[3] (or other kaliuretic agents) for the treatment of chronic heart failure or uncomplicated essential hypertension to:

  1. Help restore normal serum potassium concentrations in those who develop hypokalemia on kaliuretic therapy[4]
  2. Prevent hypokalemia in patients who would develop significant complications in the incident of hypokalemia[1]

Amiloride might also be useful as an off-label indication in Liddle syndrome,[5] thiazolidinediones-induced edema, lithium-induced polyuria, cystic fibrosis, insulin-induced edema, and multiple myeloma.[5][6][7][8][9]

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Amiloride works by inhibiting the epithelial sodium channels (ENaC) in the distal nephron (distal convoluted tubule and cortical collecting duct), lung, and colon. These ENaCs are composed of two domains that span the apical membrane. Those domains are M1 and M2. Intracellularly there C and N termini, while extracellularly, there is a large loop that contains 2 or 3 cysteine-rich domains. ENaCs consist of three subunits; alpha, beta, and gamma [10]. Mutation in beta or gamma subunits occurs in Liddle syndrome, in which basal ENaCs activity increases. Amiloride is beneficial in Liddle syndrome.[11]

Usually, sodium moves down its electrochemical gradient to enter the tubular cells through the ENaCs. This gradient results from the basolateral membrane Na/K ATPase. Reabsorption of Na is associated with depolarization of the apical membrane, which creates a lumen-negative transepithelial potential difference. This potential difference enhances potassium secretion through the apical potassium channels and, subsequently, potassium excretion. Amiloride selectively inhibits ENaCs resulting in a decrease in hyperpolarization of the apical membrane and consequently decreases potassium, hydrogen, calcium, and magnesium secretion. Because amiloride inhibits ENaCs, it can also lead to mild natriuresis.[12][13] Amiloride also has the potential to cause vasodilation.[14] Decreased renal uric acid excretion might present when using amiloride for an extended period, secondary to volume contraction and increased uric acid reabsorption in the proximal convoluted tubule.[3]

Both the loop diuretics and thiazides will lead to increased Na concentration in the distal convoluted tubule and cortical collecting duct. This increase in Na concentration couples with increased Na reabsorption as well as increased potassium secretion and excretion. Therefore, co-administration of amiloride with thiazide or loop diuretics decreases their kaliuretic effect and augments their antihypertensive and diuretic effect. 

Amiloride might be useful in treating insulin-induced edema. In this condition, there is upregulation of ENaCs, which results in increased Na reabsorption and subsequently increased potassium secretion and excretion. However, amiloride is not that effective in cases of hyperaldosteronism when compared to spironolactone and eplerenone.

Amiloride can induce apoptosis in multiple myeloma cell lines in mice, and therefore it might be used to treat relapsed multiple myeloma in the future. Also, amiloride had a synergistic effect when combined with melphalan, lenalidomide, and dexamethasone.[9]


Dosing in adults for amiloride's FDA indications:

  • Congestive heart failure: 5 to 10 mg by mouth once daily or in 2 divided doses
  • Hypertension: 5 to 10 mg  by mouth once daily or in 2 divided doses
  • Thiazide-induced hypokalemia: 5 to 10 mg by mouth once daily or in 2 divided doses

Amiloride is available as 5 mg amiloride hydrochloride tablets. It gets excreted unchanged while triamterene undergoes extensive metabolism in the liver. Oral amiloride dosing should optimally be with food to avoid gastrointestinal upset.

Special Population

  • The dosage needs to be adjusted in patients with renal impairment and contraindicated in severe renal impairment.[15]
  • It should be used cautiously in patients with diabetes and patient above 65 and older.[16]
  • There is no information provided in the product label for dose adjustment in case of hepatic impairment.
  • Amiloride is acceptable during pregnancy since it is FDA pregnancy category B.[17]
  • No information is available in the case of breastfeeding, so it is recommended to use alternative medicine.[18]

Adverse Effects

Amiloride has an FDA-boxed warning for hyperkalemia, either alone or even when combined with hydrochlorothiazide.[19] Hyperkalemia might be fatal, especially in people with diabetes mellitus, elderly patients, and patients with renal impairment. Hyperkalemia tends to occur in patients not receiving a concomitant kaliuretic diuretic. When amiloride is used concomitantly with thiazides, the risk of hyperkalemia drops to 1 to 2%. 

Other Adverse Effects [20]

  • Central nervous system: headache, fatigue, and dizziness
  • Musculoskeletal system: muscle cramps and weakness
  • Gastrointestinal system: nausea, vomiting, diarrhea/constipation, abdominal pain, and anorexia
  • Endocrine and metabolic: glucose intolerance, hyperuricemia as a side effect of all potassium-sparing diuretics including amiloride, hyperchloremic metabolic acidosis, hyponatremia, and gynecomastia. 
  • Respiratory: dyspnea and cough
  • Genitourinary: impotence


  • Amiloride can cause fatal hyperkalemia in susceptible patients.[21]
  • It is contraindicated to use amiloride in the following conditions: Chronic renal insufficiency, concomitant use of drugs that blunt the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors, beta-blockers, NSAIDs, and aliskiren), concomitant use of other potassium-sparing diuretics, anuria, diabetic nephropathy, and hypersensitivity to amiloride.[22][23][24] 
  • The clinician should discontinue oral vitamin K administration in patients receiving potassium-sparing diuretics.


Amiloride requires monitoring for hyperkalemia and impaired renal function.[17] Therefore, periodic monitoring of serum potassium concentrations and serum BUN and creatinine concentrations is crucial. The following also require monitoring: serum bicarbonate, blood pressure, serum magnesium concentrations, daily weight, and signs or symptoms of hyperkalemia.


The most toxic effect of amiloride is hyperkalemia. A rapid increase in the extracellular potassium leads to an increase in cardiac conduction velocity, which lowers the threshold for rapid phase Na-dependent depolarization. Furthermore, after the initial increase in cardiac conduction velocity, there will be a prolongation of phase-4 diastolic depolarization and shortening of the action potential, which leads to a delay in the conduction in the atrioventricular node and His-Purkinje system. On ECG, it manifests as a peaked "tented" T wave. As the condition worsens, the QRS complex will widen, resulting in the so-called ''sine-wave''. Therefore hyperkalemia can lead to increased cardiac excitability or a decrease in cardiac excitability. Increased cardiac excitation can lead to ventricular tachycardia and ventricular fibrillation, while a decrease in cardiac depression leads to various degrees of heart block and asystole.[25] Hyperkalemia can also cause an absence of the P wave on ECG.[26][27] Moreover, patients with hyperkalemia may present with fatigue, dizziness, and weakness.[27]

The initial step in managing amiloride toxicity is to stop all drugs that increase potassium concentrations (including amiloride). The next step is to treat hyperkalemia with 10 mL of 10% calcium gluconate IV over 5 minutes. Because the effect is temporary, another dose might be necessary after 15 minutes. Additionally, treating hyperkalemia includes administering rapid-acting insulin, glucose, potassium-binding resins, salbutamol, and sodium bicarbonate.[26] Normal saline may be administered for volume replacement, and if the patient is hypotensive, dopamine and norepinephrine might be appropriate.

Enhancing Healthcare Team Outcomes

Healthcare workers who prescribe amiloride should be aware of its indications, dosage, contraindication, and adverse effects. Periodic monitoring of serum potassium and renal function is an integral part of managing heart failure and hypertension when receiving amiloride. In addition, management of hypertension usually involves prescribing angiotensin-converting enzyme (ACE) inhibitors. Nevertheless, concomitant use of amiloride and ACE inhibitors carries a significant risk of developing symptomatic hyperkalemia.

When a clinician (MD, DO, NP, PA) initiates amiloride therapy, they should collaborate with other healthcare team members to enhance care coordination and communication. It is prudent to work with a pharmacist and coordinate with the lab for necessary blood values pertinent to amiloride monitoring (e.g., potassium). The pharmacist should also perform medication reconciliation and check for drug interactions and verify dosing. Nursing staff should also have involvement, including patient counseling, monitoring medication adherence, and being aware and alert to signs of adverse events and toxicity. When using amiloride for its indicated purpose, it is necessary to have a collaborative interprofessional team that includes physicians, specialty-trained nursing, and pharmacists to monitor therapy and achieve optimal patient outcomes. [Level 5]



Vidt DG. Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic. Pharmacotherapy. 1981 Nov-Dec:1(3):179-87     [PubMed PMID: 6927605]


Vesell ES, Beyer KH Jr. Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus. Toxicology. 2000 Apr 3:144(1-3):5-11     [PubMed PMID: 10781866]

Level 3 (low-level) evidence


Sun Q, Sever P. Amiloride: A review. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2020 Oct-Dec:21(4):1470320320975893. doi: 10.1177/1470320320975893. Epub     [PubMed PMID: 33234024]


Sethy VH, Patel DG, Doshi JC, Mehta JM, Sheth UK. The potassium-sparing effect of amiloride hydrochloride (MK-870) on the kaliuretic effect of ethacrynic acid. The Journal of clinical pharmacology and the journal of new drugs. 1968 Sep-Oct:8(5):309-14     [PubMed PMID: 5244660]


Tetti M, Monticone S, Burrello J, Matarazzo P, Veglio F, Pasini B, Jeunemaitre X, Mulatero P. Liddle Syndrome: Review of the Literature and Description of a New Case. International journal of molecular sciences. 2018 Mar 11:19(3):. doi: 10.3390/ijms19030812. Epub 2018 Mar 11     [PubMed PMID: 29534496]

Level 3 (low-level) evidence


Viswanathan V, Mohan V, Subramani P, Parthasarathy N, Subramaniyam G, Manoharan D, Sundaramoorthy C, Gnudi L, Karalliedde J, Viberti G. Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes. Clinical journal of the American Society of Nephrology : CJASN. 2013 Feb:8(2):225-32. doi: 10.2215/CJN.06330612. Epub 2012 Nov 26     [PubMed PMID: 23184569]

Level 1 (high-level) evidence


Pattanayak RD, Rajhans P, Shakya P, Gautam N, Khandelwal SK. Lithium-induced polyuria and amiloride: Key issues and considerations. Indian journal of psychiatry. 2017 Jul-Sep:59(3):391-392. doi: 10.4103/psychiatry.IndianJPsychiatry_168_17. Epub     [PubMed PMID: 29085107]


Tomkiewicz RP, App EM, Zayas JG, Ramirez O, Church N, Boucher RC, Knowles MR, King M. Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum. The American review of respiratory disease. 1993 Oct:148(4 Pt 1):1002-7     [PubMed PMID: 8214916]

Level 1 (high-level) evidence


Rojas EA, Corchete LA, San-Segundo L, Martínez-Blanch JF, Codoñer FM, Paíno T, Puig N, García-Sanz R, Mateos MV, Ocio EM, Misiewicz-Krzeminska I, Gutiérrez NC. Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Nov 1:23(21):6602-6615. doi: 10.1158/1078-0432.CCR-17-0678. Epub 2017 Aug 8     [PubMed PMID: 28790111]


Kashlan OB, Sheng S, Kleyman TR. On the interaction between amiloride and its putative alpha-subunit epithelial Na+ channel binding site. The Journal of biological chemistry. 2005 Jul 15:280(28):26206-15     [PubMed PMID: 15908426]

Level 3 (low-level) evidence


Aziz DA, Memon F, Rahman A, Ali M. Liddle's Syndrome. Journal of Ayub Medical College, Abbottabad : JAMC. 2016 Oct-Dec:28(4):809-811     [PubMed PMID: 28586600]


Kleyman TR, Cragoe EJ Jr. The mechanism of action of amiloride. Seminars in nephrology. 1988 Sep:8(3):242-8     [PubMed PMID: 2849182]

Level 3 (low-level) evidence


Shah SU, Anjum S, Littler WA. Use of diuretics in cardiovascular diseases: (1) heart failure. Postgraduate medical journal. 2004 Apr:80(942):201-5     [PubMed PMID: 15082840]


Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. Journal of clinical hypertension (Greenwich, Conn.). 2011 Sep:13(9):644-8. doi: 10.1111/j.1751-7176.2011.00511.x. Epub 2011 Aug 9     [PubMed PMID: 21896143]


Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun:71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13     [PubMed PMID: 29133356]

Level 1 (high-level) evidence


By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2019 Apr:67(4):674-694. doi: 10.1111/jgs.15767. Epub 2019 Jan 29     [PubMed PMID: 30693946]


Krysiak R, Samborek M, Stojko R. Primary aldosteronism in pregnancy. Acta clinica Belgica. 2012 Mar-Apr:67(2):130-4     [PubMed PMID: 22712170]

Level 3 (low-level) evidence


. Amiloride. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 30000009]


Wan HH, Lye MD. Moduretic-induced metabolic acidosis and hyperkalaemia. Postgraduate medical journal. 1980 May:56(655):348-50     [PubMed PMID: 7443596]

Level 3 (low-level) evidence


Arai AE, Greenberg BH. Medical management of congestive heart failure. The Western journal of medicine. 1990 Oct:153(4):406-14     [PubMed PMID: 2244376]


Berkova M, Berka Z, Topinkova E. Arrhythmias and ECG changes in life threatening hyperkalemia in older patients treated by potassium sparing drugs. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2014:158(1):84-91. doi: 10.5507/bp.2012.087. Epub 2012 Oct 31     [PubMed PMID: 23128820]

Level 3 (low-level) evidence


Spahn H, Reuter K, Mutschler E, Gerok W, Knauf H. Pharmacokinetics of amiloride in renal and hepatic disease. European journal of clinical pharmacology. 1987:33(5):493-8     [PubMed PMID: 3428342]


Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J. Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients. European journal of clinical pharmacology. 1986:30(2):151-6     [PubMed PMID: 3519243]

Level 1 (high-level) evidence


Andersen H, Hansen PB, Bistrup C, Nielsen F, Henriksen JE, Jensen BL. Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy. Journal of hypertension. 2016 Aug:34(8):1621-9. doi: 10.1097/HJH.0000000000000967. Epub     [PubMed PMID: 27214087]


Montford JR, Linas S. How Dangerous Is Hyperkalemia? Journal of the American Society of Nephrology : JASN. 2017 Nov:28(11):3155-3165. doi: 10.1681/ASN.2016121344. Epub 2017 Aug 4     [PubMed PMID: 28778861]


Kokot F, Hyla-Klekot L. Drug-induced abnormalities of potassium metabolism. Polskie Archiwum Medycyny Wewnetrznej. 2008 Jul-Aug:118(7-8):431-4     [PubMed PMID: 18714739]


Belkouch A, Belyamani L. An unusual manifestation of hyperkalemia. The Pan African medical journal. 2014:19():251. doi: 10.11604/pamj.2014.19.251.5007. Epub 2014 Nov 7     [PubMed PMID: 25852794]